Tradestie Institutional Equity Comparison Engine

URGN vs ELTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

URGN Overall Edge

URGN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to UroGen Pharma Ltd. Ordinary Shares (URGN) driven by superior Valuation, Momentum & Technical, Options & Structure while ELTX counters with relative strength in Growth & Margin. Fundamentally, URGN trades at 11.1x Forward P/E with -12.4% operating margin (+223.9% YoY revenue) versus ELTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, URGN sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against ELTX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner URGN
URGN 11.1x vs ELTX N/M Fwd P/E
Growth & Margin Winner ELTX
Op Margin -12.4% vs 0.0% ยท YoY +223.9% vs +0.0%
Momentum & Technical Winner URGN
1Y +9.4% vs -82.1% ยท 52W Pos 32% vs 1%
Options & Structure Winner URGN
CONSOLIDATION (10th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
URGN NASDAQ
UroGen Pharma Ltd. Ordinary Shares
Pharmaceutical Preparations
$27.65
-12.86% 1D
Market Cap $1.5B
1M Return -21.34%
1Y Return +9.42%
Forward P/E 11.1x
Unified AI Score
62.7 / 100 BUY
Tech 58.0 Fund 59.0 Flow 69.0 Mom 50.0
ELTX NASDAQ
Elicio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-3.33% 1D
Market Cap $42.5M
1M Return -25.26%
1Y Return -82.1%
Forward P/E N/M
Unified AI Score
53.1 / 100 HOLD
Tech 72.0 Fund 60.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: URGN +9.42% ELTX -82.1% Spread: +91.52 pp (URGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period URGN Revenue ELTX Revenue URGN Op. Margin ELTX Op. Margin Margin Edge
FY2018 $0M N/A -6842.2% N/A URGN
FY2019 $0M N/A -608211.1% N/A URGN
FY2020 $10M $0M -1074.2% -1919.2% URGN
FY2021 $50M $30M -192.1% -138.8% ELTX
FY2022 $60M $0M -122.8% -1031.4% URGN
FY2023 $80M N/A -79.2% N/A URGN
FY2024 $90M N/A -107.1% N/A URGN
FY2025 $110M N/A -113.7% N/A URGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: URGN (7) vs ELTX (3)
Institutional Metric URGN ELTX Criterion Row Winner
Market Capitalization Scale $1.5B $42.5M Larger Scale URGN
Trailing P/E Ratio Valuation 14.6x N/M Lower Multiple URGN
Forward P/E Ratio Valuation 11.1x N/M Lower Multiple URGN
Revenue Growth (YoY) Growth +223.9% +0.0% Higher Growth URGN
Operating Margin (TTM) Profitability -12.4% 0.0% Higher Margin ELTX
Net Profit Margin Profitability -26.3% 0.0% Higher Margin ELTX
Return on Equity (ROE) Capital Efficiency -1481.3% -315.3% Higher ROE ELTX
52-Week Range Position Momentum 32% ($16โ€“$51) 1% ($1โ€“$16) Stronger Trend URGN
Beta / 30D Volatility Risk Regime 1.24ฮฒ ยท 90% Vol 0.41ฮฒ ยท 92% Vol Lower Realized Risk URGN
Unified Institutional Score Composite Signal 62.7 / 100 (BUY) 53.1 / 100 (HOLD) Higher Composite URGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full URGN vs ELTX Buy Guide
URGN CONSOLIDATION
100d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live URGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ELTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ELTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither URGN nor ELTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.